Harbour Capital Advisors LLC trimmed its position in Pfizer Inc. (NYSE:PFE) by 9.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,034 shares of the biopharmaceutical company’s stock after selling 978 shares during the period. Harbour Capital Advisors LLC’s holdings in Pfizer were worth $394,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. JCIC Asset Management Inc. lifted its holdings in shares of Pfizer by 11.3% during the 3rd quarter. JCIC Asset Management Inc. now owns 276,622 shares of the biopharmaceutical company’s stock worth $12,191,000 after acquiring an additional 28,145 shares during the period. Montecito Bank & Trust lifted its holdings in shares of Pfizer by 9.7% during the 3rd quarter. Montecito Bank & Trust now owns 56,190 shares of the biopharmaceutical company’s stock worth $2,476,000 after acquiring an additional 4,951 shares during the period. Corrado Advisors LLC purchased a new position in shares of Pfizer during the 3rd quarter worth about $233,000. North Star Investment Management Corp. lifted its holdings in shares of Pfizer by 1.1% during the 3rd quarter. North Star Investment Management Corp. now owns 168,831 shares of the biopharmaceutical company’s stock worth $7,440,000 after acquiring an additional 1,905 shares during the period. Finally, DAVENPORT & Co LLC lifted its holdings in shares of Pfizer by 9.7% during the 3rd quarter. DAVENPORT & Co LLC now owns 291,958 shares of the biopharmaceutical company’s stock worth $12,867,000 after acquiring an additional 25,740 shares during the period. 69.49% of the stock is owned by institutional investors and hedge funds.

PFE opened at $39.38 on Friday. The company has a market cap of $234.42 billion, a P/E ratio of 13.13, a price-to-earnings-growth ratio of 2.54 and a beta of 0.75. Pfizer Inc. has a 1 year low of $34.37 and a 1 year high of $46.47. The company has a debt-to-equity ratio of 0.52, a current ratio of 1.57 and a quick ratio of 1.33.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 29th. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.63 by $0.01. Pfizer had a net margin of 20.79% and a return on equity of 26.02%. The firm had revenue of $13.98 billion during the quarter, compared to the consensus estimate of $13.92 billion. During the same quarter in the prior year, the company earned $0.62 EPS. The company’s revenue was up 2.0% on a year-over-year basis. On average, analysts expect that Pfizer Inc. will post 2.86 earnings per share for the current year.

In other Pfizer news, EVP Douglas M. Lankler sold 5,000 shares of the stock in a transaction that occurred on Friday, February 1st. The shares were sold at an average price of $42.75, for a total value of $213,750.00. Following the completion of the sale, the executive vice president now owns 83,592 shares of the company’s stock, valued at $3,573,558. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Douglas M. Lankler sold 38,800 shares of the stock in a transaction that occurred on Wednesday, January 30th. The shares were sold at an average price of $41.19, for a total transaction of $1,598,172.00. Following the completion of the sale, the executive vice president now directly owns 83,592 shares of the company’s stock, valued at approximately $3,443,154.48. The disclosure for this sale can be found here. Insiders sold 332,526 shares of company stock valued at $14,346,539 in the last ninety days. 0.09% of the stock is owned by corporate insiders.

Several research analysts have recently weighed in on the stock. Credit Suisse Group set a $45.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a report on Tuesday, January 1st. Cantor Fitzgerald set a $53.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a report on Sunday, December 30th. Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “hold” rating in a research report on Wednesday, April 3rd. Bank of America increased their target price on shares of Pfizer from $45.00 to $48.00 and gave the stock a “buy” rating in a research report on Monday, April 1st. Finally, Citigroup reissued a “neutral” rating and set a $41.00 target price on shares of Pfizer in a research report on Wednesday, February 20th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and seven have issued a buy rating to the company. Pfizer presently has an average rating of “Hold” and a consensus price target of $45.61.

WARNING: This article was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://theolympiareport.com/2019/04/20/pfizer-inc-pfe-shares-sold-by-harbour-capital-advisors-llc.html.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Read More: Lock-Up Period Expiration

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.